Spectrum Drug Patent Portfolio
Spectrum's Family Patents
Clinical Trials
Recent Clinical Trials by Spectrum:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | Spectrum Pharmaceuticals, Inc | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | Spectrum Pharmaceuticals, Inc | NA |
SUSPENDED
(Aug 1, 2026)
| PHASE3 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List